Latest profit margin for Nautilus Biotechnology: -13816.75% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
Nautilus Biotechnology (NAUT) currently reports a profit margin of -13816.75% as of September 2026. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore Nautilus Biotechnology's profit margin history and peer comparisons.
Nautilus Biotechnology's profit margin of -13816.75% is lower than the Healthcare sector average of 17.63%. That is roughly 78477.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Nautilus Biotechnology's current -13816.75% should be judged against Healthcare norms (sector average: 17.63%) and against NAUT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -13816.75%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for Nautilus Biotechnology, and consider following NAUT for alerts when major investors trade the stock.
Nautilus Biotechnology is classified in the Healthcare sector. On profit margin, it currently shows -13816.75% versus a sector average near 17.63%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NAUT with unrelated industries.